Polycystic Kidney Disease News and Research RSS Feed - Polycystic Kidney Disease News and Research

Mild reduction in food intake slows development of autosomal-dominant polycystic kidney disease

Mild reduction in food intake slows development of autosomal-dominant polycystic kidney disease

A small reduction in food intake—less than required to cause weight loss—dramatically slowed the development of a common genetic disorder called autosomal-dominant polycystic kidney disease (ADPKD) in mice, a new study in American Journal of Physiology—Renal Physiology reports. [More]
JINARC (tolvaptan) accepted for use in Scotland for ADPKD treatment

JINARC (tolvaptan) accepted for use in Scotland for ADPKD treatment

From today, people in Scotland with the genetic kidney disease ADPKD could benefit from JINARC® (tolvaptan) following advice issued by the Scottish Medicines Consortium (SMC) for its use in adults with chronic kidney disease (CKD) stages 1-3 at the start of treatment with evidence of rapidly progressing disease. [More]
Rutgers scientists uncover biological pathways that provide insight into tiny cell bubbles

Rutgers scientists uncover biological pathways that provide insight into tiny cell bubbles

Rutgers scientists have uncovered biological pathways in the roundworm that provide insight into how tiny bubbles released by cells can have beneficial health effects, like promoting tissue repair, or may play a diabolical role and carry disease signals for cancer or neurodegenerative diseases like Alzheimer's. [More]
CRISPR/Cas9 turns hPSCs into cell-based lab model system for polycystic kidney disease

CRISPR/Cas9 turns hPSCs into cell-based lab model system for polycystic kidney disease

CRISPR/Cas9 is hot. News of the revolutionary gene editing technique that is already shaking up bioscience has finally reached the news media and the public. Now comes a first rate example of how CRISPR is changing the pace of biomedical research by linking up with another cutting edge technology -- human pluripotent stem cells (hPSCs). [More]
Stem cell biology and gene-editing techniques offer hope for kidney regeneration

Stem cell biology and gene-editing techniques offer hope for kidney regeneration

Mini-kidney organoids have now been grown in a laboratory by using genome editing to re-create human kidney disease in petri dishes. [More]
FDA awards research grants to boost product development for patients with rare diseases

FDA awards research grants to boost product development for patients with rare diseases

The U.S. Food and Drug Administration today announced it has awarded 18 new research grants totaling more than $19 million to boost the development of products for patients with rare diseases, which affect the lives of nearly 30 million Americans. [More]
Aggressive blood pressure treatment can reduce risks of heart disease and death

Aggressive blood pressure treatment can reduce risks of heart disease and death

Loyola University Chicago is among the centers participating in a landmark clinical trial that has found that more intensive management of high blood pressure reduces heart disease rates and saves lives. [More]
UT Southwestern researchers part of study that shows effectiveness of intensive blood pressure management

UT Southwestern researchers part of study that shows effectiveness of intensive blood pressure management

More intensive management of high blood pressure, below a commonly recommended blood pressure target, significantly reduces rates of cardiovascular disease, and lowers risk of death in a group of adults 50 years and older with high blood pressure, a National Institutes of Health study involving UT Southwestern Medical Center researchers shows. [More]
3SBio purchases entire equity interest in Zhejiang Wansheng

3SBio purchases entire equity interest in Zhejiang Wansheng

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the entire equity interest in Zhejiang Wansheng Pharmaceutical Co., Ltd a limited liability company incorporated in the PRC for an aggregate consideration of RMB 528 million. [More]
UC Santa Barbara professor develops novel therapeutic strategy for PKD

UC Santa Barbara professor develops novel therapeutic strategy for PKD

For the 12 million people worldwide who suffer from polycystic kidney disease (PKD), an inherited disorder with no known cure, a new treatment option may be on the horizon. [More]
New technique slows progression of polycystic kidney disease in mice

New technique slows progression of polycystic kidney disease in mice

A new technique for treating polycystic kidney disease has been identified by researchers based at the UCL Institute of Child Health. Published in the Journal of the American Society of Nephrology, the treatment, which involves targeting tiny blood and lymphatic vessels inside the kidneys, is shown to improve renal function and slow progression of disease in mice. [More]
Manchester, UCL researchers discover new technique for treating polycystic kidney disease

Manchester, UCL researchers discover new technique for treating polycystic kidney disease

A new technique for treating polycystic kidney disease has been identified by researchers at The University of Manchester and UCL. [More]
First European approval of drug to treat genetic kidney disease ADPKD

First European approval of drug to treat genetic kidney disease ADPKD

Otsuka Pharmaceutical Co., Ltd. announced that the European Commission has granted marketing authorisation for JINARC® (tolvaptan) for the treatment of ADPKD in adults who have chronic kidney disease (CKD) stage one to three at initiation of treatment with evidence of rapidly progressing disease [More]
Managing autosomal dominant polycystic kidney disease: an interview with Dr Richard Sandford, University of Cambridge

Managing autosomal dominant polycystic kidney disease: an interview with Dr Richard Sandford, University of Cambridge

Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common inherited kidney diseases. It's also one of the most common reasons that people require dialysis or transplantation... [More]
DFG selects 10 researchers to receive 2015 Heinz Maier-Leibnitz Prize

DFG selects 10 researchers to receive 2015 Heinz Maier-Leibnitz Prize

This year's recipients of the most important prize for early career researchers in Germany have been announced. The selection committee, appointed by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) and the German Federal Ministry of Education and Research (BMBF), has chosen ten researchers, five women and five men, to receive the 2015 Heinz Maier-Leibnitz Prizes. [More]
Today’s “World Kidney Day” promotes kidney health for all

Today’s “World Kidney Day” promotes kidney health for all

Recent surveys have shown that the general public’s understanding about what our kidneys do and what the risk factors for kidney disease are, is astoundingly poor. In the UK, five leading kidney charities are joining forces in the campaign “Kidney Charities Together,” which calls for urgent action to be taken to raise awareness of kidney disease. [More]

EMA's CHMP backs JINARC (tolvaptan) for autosomal dominant polycystic kidney disease

Otsuka Pharmaceutical Co., Ltd. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended JINARC (tolvaptan) for approval. [More]

Brandeis University researchers capture highest resolution images of cilia ever

Cilia, the cell's tails and antennas, are among the most important biological structures. They line our windpipe and sweep away all the junk we inhale; they help us see, smell and reproduce. When a mutation disrupts the function or structure of cilia, the effects on the human body are devastating and sometimes lethal. [More]
NIH study finds limited kidney benefit from more rigorous blood pressure treatment

NIH study finds limited kidney benefit from more rigorous blood pressure treatment

Using two drugs was no more effective than a single drug in slowing disease progression in people with autosomal dominant polycystic kidney disease (ADPKD), according to two studies funded by the National Institutes of Health. One of the studies also showed that rigorous blood pressure treatment slowed growth of kidney cysts, a marker of ADPKD, but had little effect on kidney function compared to standard blood pressure treatment. [More]
Otsuka Pharmaceutical begins tolvaptan Phase 3b study in patients with ADPKD

Otsuka Pharmaceutical begins tolvaptan Phase 3b study in patients with ADPKD

Otsuka Pharmaceutical Development & Commercialization, Inc., announced today that patient enrollment has begun for a new Phase 3b study of tolvaptan for adult patients with autosomal dominant polycystic kidney disease (ADPKD), the most common, life-threatening, inherited genetic kidney disorder. [More]
Advertisement
Advertisement